Thomas Smith
Stock Analyst at Leerink Partners
(2.55)
# 2,630
Out of 5,182 analysts
59
Total ratings
35.59%
Success rate
20.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $49 → $106 | $68.63 | +54.45% | 1 | Apr 13, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $10.64 | +238.35% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $5.01 | +139.52% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $24.02 | +33.22% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $25.58 | +64.19% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $2.05 | -51.22% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $5.72 | +57.34% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $4.22 | +65.88% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.80 | +473.53% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $8.75 | +197.14% | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $109.87 | -81.80% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $775.03 | -43.87% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $67.26 | -46.48% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.40 | +191.67% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $26.99 | -22.19% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.61 | +230.64% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $13.84 | -56.65% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.79 | +115.05% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $90 → $50 | $10.75 | +365.12% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $16.66 | +2.04% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $33.23 | +92.60% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.14 | +285.89% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.48 | +647.13% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $32.39 | -62.95% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $11.37 | +603.61% | 2 | Dec 8, 2020 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Outperform
Price Target: $49 → $106
Current: $68.63
Upside: +54.45%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $10.64
Upside: +238.35%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $5.01
Upside: +139.52%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $24.02
Upside: +33.22%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $25.58
Upside: +64.19%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $2.05
Upside: -51.22%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $5.72
Upside: +57.34%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $4.22
Upside: +65.88%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.80
Upside: +473.53%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $8.75
Upside: +197.14%
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $109.87
Upside: -81.80%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $775.03
Upside: -43.87%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $67.26
Upside: -46.48%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.40
Upside: +191.67%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.99
Upside: -22.19%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $13.61
Upside: +230.64%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $13.84
Upside: -56.65%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.79
Upside: +115.05%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $90 → $50
Current: $10.75
Upside: +365.12%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $16.66
Upside: +2.04%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $33.23
Upside: +92.60%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.14
Upside: +285.89%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.48
Upside: +647.13%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $32.39
Upside: -62.95%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $11.37
Upside: +603.61%